Close Menu

NEW YORK – Cambridge, Massachusetts-based Ymir Genomics said on Wednesday that it has signed a licensing agreement and filed a joint patent application with the Oregon Health & Science University's Knight Cancer Institute that aims to protect and promote newly discovered urinary biomarkers for cirrhosis or hepatocellular carcinoma (HCC).

Ymir and OHSU will share in any value created by the biomarkers and will jointly publish and validate the biomarkers in a large-scale multi-center study.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Science reports that Science Foundation Ireland is seeking annual budget increases.

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.